Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

@article{Schmid2003RandomizedTO,
  title={Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.},
  author={Marianne Schmid and Raimund Jakesz and Hellmut Samonigg and Ernst Kubista and Michael Gnant and Christian Menzel and Michael J. Seifert and Karin Haider and Susanne Taucher and Brigitte Mlineritsch and Peter Steindorfer and Werner Kwasny and Michael Stierer and Christoph Tausch and Michael A Fridrik and Viktor M. Wette and Guenther G. Steger and Hubert Hausmaninger},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 6},
  pages={984-90}
}
PURPOSE To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer. PATIENTS AND METHODS A total of 2,021 postmenopausal women were randomly assigned to receive either tamoxifen for 5 years alone or tamoxifen in combination with aminoglutethimide (500 mg/d) for the first 2 years of treatment. Tamoxifen was administered at 40 mg/d for the first 2 years and at 20 mg/d for… CONTINUE READING
21 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…